Recent Updates
Recently added Catalysts

Gintuit,Autologous palatal tissue

Phase 3

Gingival Recession | Unknown | Other |Organogenesis Holdings Inc.|Last Updated: Nov 7, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment96
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00587834Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue RegenerationPHASE3 COMPLETED 96Oct 1, 2007Dec 1, 2008Nov 7, 2012 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
GintuitDEVICEApplication of Gintuit at Day 0 to the gingival bed
Autologous palatal tissueOTHERTissue will be harvested from the subject's palate and placed on the gingival bed
Unlock Study Design Details